Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS-04 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback